2023 Q2 Financial Review


Jul. 26, 2023

Disclaimer

- Except for statements in respect of historical matters, the statements in this release are forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual performance, financial condition or results of operations of Unimicron to be materially different from what may be implied by such forward-looking statements.
- The financial forecasts and forward-looking statements in this release reflect the current belief of Unimicron as of the date of this release and Unimicron undertakes no obligation to update these forecasts and forward-looking statements for events or circumstances that occur subsequent to such date.
- The statements in respect of historical matters may contain unaudited information, which may have certain deficiency or weakness so as not to fairly present financial condition or the result of operations of Unimicron.



Consolidated Sales & Gross Margin Trend



3

CONFIDENTIAL

Consolidated Statements of Comprehensive Income – QoQ

	Q2-23	%	Q1-23	%	NTD:M QoQ %
Net Sales	25,235	100.0	26,566	100.0	(5)
Cost of sales	(20,134)	(79.8)	(21,104)	(79.4)	(5)
Gross Profit	5,101	20.2	5,462	20.6	(7)
Operating Expenses	(2,746)	(10.9)	(2,563)	(9.7)	7
Other Income and Expenses	2	0.0	6	0.0	(67)
Operating Income	2,357	9.3	2,905	10.9	(19)
Net Non-operating Income and Expenses	1,097	4.4	2,271	8.6	(52)
Income before tax	3,454	13.7	5,176	19.5	(33)
Income Tax Expense	(984)	(3.9)	(984)	(3.7)	0
Net Income	2,470	9.8	4,192	15.8	(41)
Other Comprehensive Income and Losses	(1,022)	(4.1)	261	1.0	(492)
Comprehensive Income	1,448	5.7	4,453	16.8	(67)
Net Income (Loss) Attributable to:					
Shareholders of the Parent	2,389	9.5	4,095	15.4	
Non-controlling Interests	81	0.3	97	0.4	
Net Income	2,470	9.8	4,192	15.8	
EBITDA	7,319		8,923		
%(Sales)	29%		34%		
EPS (Basic)	1.57		2.70		
(Diluted)	1.56		2.68		

CONFIDENTIAL

Consolidated Statements of Comprehensive Income – YoY

					NTD:M
-	H1-23	%	H1-22	%	YoY %
Net Sales	51,801	100.0	66,346	100.0	(22)
Cost of sales	(41,238)	(79.6)	(42,954)	(64.7)	(4)
Gross Profit	10,563	20.4	23,392	35.3	(55)
Operating Expenses	(5,309)	(10.2)	(5,918)	(9.0)	(10)
Other Income and Expenses	8	0.0	65	0.1	(88)
Operating Income (Loss)	5,262	10.2	17,539	26.4	(70)
Net Non-operating Income and Expenses	3,368	6.5	1,060	1.6	218
Income (Loss) before tax	8,630	16.7	18,599	28.0	(54)
Income Tax (Expense) Benefit	(1,968)	(3.8)	(4,325)	(6.5)	(54)
Net Income (Loss)	6,662	12.9	14,274	21.5	(53)
Other Comprehensive Income and Losses	(761)	(1.5)	(240)	(0.3)	(217)
Comprehensive Income (Loss)	5,901	11.4	14,034	21.2	(58)
Net Income (Loss) Attributable to:					
Shareholders of the Parent	6,484	12.5	13,697	20.6	
Non-controlling Interests	178	0.4	577	0.9	
Net Income (Loss)	6,662	12.9	14,274	21.5	
EBITDA	16,243		24,243		
%(Sales)	31%		37%		
EPS (Basic)	4.27		9.28		
(Diluted)	4.23		9.15		

5 CONFIDENTIAL

Consolidated Balance Sheets

	2023	0/	2023	0/	2022	NTD:M
	JUN.30	<u>%</u>	MAR.31	<u>%</u>	DEC.31	<u>%</u>
Cash	63,611	29.4	67,732	30.4	61,459	28.1
Accounts Receivable	21,444	9.6	20,936	9.4	28,746	13.1
Inventories	9,443	4.3	10,234	4.6	12,835	5.9
Other Current Assets	3,722	1.7	3,716	1.7	4,548	2.1
Long-term Investments	7,901	3.5	7,654	3.4	8,552	3.9
Fixed Assets & Investment Property	104,775	47.0	102,839	46.2	94,510	43.2
Total Assets	220,868	100.0	222,516	100.0	218,663	100.0
Short-term Loans	3,623	2.0	4,967	2.2	7,945	3.6
Long-term Loans-Current	2,816	1.3	2,788	1.3	2,411	1.1
Other Current Liabilities	51,224	22.1	40,417	18.2	44,537	20.4
Long-term Loans	24,065	11.3	25,488	11.5	24,563	11.2
Other Long-term Liabilities	48,693	22.4	47,966	21.6	46,549	21.3
Shareholders' Equity	90,447	40.9	100,890	45.3	92,658	42.4
Net Inventory						
Turnover Days	49		50		51	
Net Accounts Receivable						
Turnover Days	88		85		68	

6 CONFIDENTIAL

Consolidated Statements Of Cash Flows – QoQ

	Q2-23	NTD:M Q1-23
Income before tax	3,454	5,176
Depreciation and Amortization	3,713	3,572
Others	(1,265)	5,397
Net Cash Provided by Operating Activities	5,902	14,145
Acquisition of Fix Assets & Investment Property	(4,727)	(5,699)
Increase in Investments	(19)	(2)
Others	(1,745)	1,551
Net Cash Used by Investing Activities	(6,491)	(4,150)
Decrease in Loans	(2,675)	(3,659)
Others	67	(167)
Net Cash Used by Financing Activities	(2,608)	(3,826)
Effect of Exchange Rates Changes	(923)	104
Increase (Decrease) in Cash	(4,120)	6,273
Cash at End of Period	63,611	67,732


Unimicron

Consolidated Statements Of Cash Flows – YoY

	H1-23	NTD:M H1-22
Income before tax	8,630	18,599
Depreciation and Amortization	7,285	5,482
Others	4,132	3,374
Net Cash Provided by Operating Activities	20,047	27,455
Acquisition of Fix Assets & Investment Property	(10,427)	(16,949)
Increase in Investments	(21)	(203)
Others	(193)	539
Net Cash Used by Investing Activities	(10,641)	(16,613)
Decrease in Loans	(6,334)	(3,682)
Increase in Corporate Bond	0	2,996
Others	(100)	421
Net Cash Used by Financing Activities	(6,434)	(265)
Effect of Exchange Rates Changes	(820)	(352)
Increase in Cash	2,152	10,225
Cash at End of Period	63,611	49,626


Unimicron

Sales Breakdown by Technology - QoQ




CONFIDENTIAL

Sales Breakdown by Application - QoQ






Sales Breakdown by Technology - YoY



Unimicron

Sales Breakdown by Application - YoY





謝謝您的聆聽

Unimicron

Thank you